
Liver-on-Chip Platforms: Recreating Human Physiology for Predictive Drug Development
Re-Engineering the Liver Microenvironment In the first article of this series, we discussed the limitations of
Re-Engineering the Liver Microenvironment In the first article of this series, we discussed the limitations of
The liver organoid is transforming how researchers approach drug discovery and safety testing. As miniature, three-dimensional
Understanding how the body processes fats is central to tackling obesity, type 2 diabetes, and fatty
Breast cancer remains the most common malignancy in women worldwide, and progress in treatment increasingly depends
Breast cancer is the second cancer-related cause of death in women worldwide, therefore it is no
Introduction Microphysiological systems (MPS) are fast becoming a cornerstone of FDA-aligned non-clinical strategy, especially when paired
Introduction Organoid and artificial intelligence approaches are central to the FDA’s roadmap for reducing animal use
Introduction Adipose tissue-breast cancer crosstalk is emerging as a key driver of tumor initiation, progression, and
Introduction Following our articles on how breast cancer organoids and breast‑cancer‑on‑chip platforms expand beyond conventional 2D and
3D breast cancer models are rapidly redefining how we investigate the world’s deadliest malignancy in women,
14 rue de la Beaune,
93100 Montreuil (Paris)
France
+33 9 87 04 70 35
contact@cherrybiotech.com
All right reserved to © Cherry Biotech 2023